The voluntary nationwide recall stems from elevated levels of impurity detected during recent routine quality testing. No adverse events have been reported. However, elevated impurities have the potential to result in neuromuscular blockage in patients with renal failure.
Affected lots were distributed between January and May 2012.
More Articles on Anesthesia:
California Society of Anesthesiologists Elects Dr. Peter Sybert President
Congress Looks at SGR Repeal, Must Also Tackle Anesthesiologists’ 33% Problem Prior
FDA Investigates Fungal Infection Associated with Tennessee Compounding Pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
